CD8A and lymphoma: In contrast with the lymphoma models, ICBs-CT26 treatment did not induce changes in classical CD8+ nor CD4+ populations, however did induce significant increase of CD4+CD25+FoXP3 and CD4+ Tbet+ subpopulation in the spleen, without changes in CD4+ROR-γt+ subpopulations (Figure 9).